Thyroid Cancer

SELECT: Lenvatinib Improves Outcomes as First-Line Treatment in Older Patients with Thyroid Cancer

Alice Goodman

September 2015, Vol 6, No 8 - Thyroid Cancer

Chicago, IL—Lenvatinib (Lenvima) was approved by the FDA in February 2015 for the treatment of patients with advanced radioactive iodine (131I)-­refractory differentiated thyroid cancer based on the SELECT trial results. Investigators looked at which patients will preferentially benefit from this oral tyrosine kinase inhibitor (TKI). At the 2015 American Society of Clinical Oncology meeting, 2 subgroup analyses of SELECT shed light on patient selection for treatment with lenvatinib. [ Read More ]